Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 22-year-old male has been using oral dutasteride, oral minoxidil, topical minoxidil, and supplements for hair loss, experiencing shedding but some regrowth on the temples. Despite concerns about starting dutasteride, he is seeing positive results and hopes for long-term success.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.

Dutasteride is more effective in gel capsule form due to better absorption, as it is fat-soluble. If only pills are available, taking them with fat or increasing the dose slightly may help.

Fluridil was abandoned due to its weak effectiveness and low binding affinity to the androgen receptor, making it less competitive against DHT and testosterone. Users discuss its limited results compared to other treatments like pyrilutamide and RU58841.

A user inquired about purchasing KX-826 for hair loss if approved in China. Another user provided links to purchase it without waiting for U.S. approval.

The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.

RU58841 was the only treatment that slowed hair loss and reduced irritation for a DUPA sufferer after trying finasteride, minoxidil, and dutasteride with no success. The user continues using 6mg oral minoxidil, 0.5mg dutasteride, and an 8% RU58841 solution.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

The user is asking if it's safe to use a glass dropper from a finished RU58841 product with a new RU58841 product and if cleaning it with water is sufficient. They are concerned about the quality of the plastic dropper that came with the new product.

The conversation discusses the anticipation and skepticism around the release of GT20029 for hair loss treatment. The original poster has been using Finasteride and Minoxidil but is hopeful for GT20029, while others express doubts about its timely release and suggest alternatives like KX826 and hair transplants.

The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

RU58841 is discussed as an effective hair loss treatment, with some users experiencing regrowth and reduced shedding, but concerns about safety and sourcing are raised. Users advise against purchasing from Amazon, recommending reputable sources and cautioning about potential side effects like cardiovascular issues.

The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.

The conversation is about using RU58841 for hair loss, discussing the stability of the powder form and the need for a carrier solution like KB or PG + ethanol. The user is advised to mix RU58841 with stemoxydine and store it properly, while also considering safety precautions.

A 22-year-old male has been using Dutasteride 0.5 mg every other day and Minoxidil 5% daily since December 2024 for hair loss, with no side effects reported. Users discuss varying dosages of Dutasteride, with some expressing concerns about higher doses.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

The user experienced hair loss after adding estradiol (in ALPICORT E) to their finasteride and minoxidil regimen, which initially provided almost full regrowth. The doctor advised using estradiol for 3 months, but users questioned the rationale and suggested sticking with finasteride and minoxidil.

An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.

OP developed hives after using Kx 826 (Pyrilutamide) 1% twice daily for 3 weeks. The hives appeared on the arms, chest, and groin area.

The user has been using pyrilutamide 0.5% for over 7 weeks, alongside dutasteride, and noticed some hair improvement, particularly at the temples. They plan to continue and possibly try a 1% solution, with no shedding or side effects reported.

Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.

KY19382 is discussed as a potential treatment for creating new hair follicles and possibly curing hair loss. The conversation seeks user experiences and sourcing information for KY19382.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

The conversation discusses using Sandalore for hair loss treatment, with a focus on finding the correct concentration for a topical lotion. The consensus is to start with a 0.1% concentration due to potential scalp irritation at higher levels.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

A 22-year-old man has been using topical Minoxidil 5% twice daily and Finasteride 1 mg daily for about a month and three weeks, noticing new hair growth. He plans to add saw palmetto and Ketoconazole shampoo to his regimen.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.